CBD reversed amphetamine-induced brain damage in a rat model of mania
CBD reversed oxidative brain damage caused by amphetamine in rats and increased BDNF, a protein important for brain cell health, suggesting mood-stabilizing potential.
Quick Facts
What This Study Found
Researchers used two experimental models in rats. In the reversal model, rats received amphetamine daily for 14 days (to mimic mania), then received CBD (15, 30, or 60 mg/kg) from day 8 to 14. In the prevention model, CBD was given first, followed by amphetamine from day 8 to 14.
In the reversal model, CBD at 15 mg/kg reversed amphetamine-induced oxidative damage in the hippocampus and increased brain-derived neurotrophic factor (BDNF) at 30 mg/kg. In the prevention model, CBD at 30 or 60 mg/kg prevented oxidative protein damage in the prefrontal cortex, and all CBD doses prevented damage in the hippocampus and striatum.
Notably, CBD did not reduce amphetamine-induced hyperactivity in either model, suggesting its neuroprotective effects were independent of behavioral changes.
Key Numbers
CBD 15 mg/kg reversed hippocampal oxidative damage. CBD 30 mg/kg increased BDNF. CBD 30-60 mg/kg prevented prefrontal cortex damage. All doses (15, 30, 60 mg/kg) prevented hippocampal and striatal damage in the prevention model.
How They Did This
Two rat models of mania: reversal (CBD given during ongoing amphetamine) and prevention (CBD given before amphetamine). CBD at 15, 30, and 60 mg/kg was administered twice daily. Oxidative damage markers, BDNF levels, and locomotor activity were measured.
Why This Research Matters
Bipolar disorder involves oxidative stress and reduced BDNF in the brain. If CBD can protect against these changes, it might function as a neuroprotective adjunct to standard mood stabilizers, addressing brain health rather than just symptom control.
The Bigger Picture
Standard mood stabilizers (lithium, valproate) also have neuroprotective properties. The finding that CBD shares some of these properties opened questions about whether it could complement existing treatments, particularly in protecting against the brain damage associated with manic episodes.
What This Study Doesn't Tell Us
Amphetamine-induced hyperactivity is a limited model of bipolar mania. CBD did not reduce hyperactivity, raising questions about behavioral relevance. Rat brain responses may not translate to human bipolar disorder. Dosing and timing may not apply clinically.
Questions This Raises
- ?Why did CBD protect brain cells without affecting behavior?
- ?Could CBD be useful as an adjunct to mood stabilizers for neuroprotection?
- ?What is the clinical significance of BDNF increases from CBD?
Trust & Context
- Key Stat:
- CBD increased BDNF, a key protein for brain cell health
- Evidence Grade:
- Animal study using a pharmacological model of mania. Provides mechanistic data but limited clinical applicability. Multiple dose levels and two models strengthen internal validity.
- Study Age:
- Published in 2011. CBD research for mood disorders has continued, with some small clinical trials conducted since.
- Original Title:
- Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania.
- Published In:
- Journal of psychopharmacology (Oxford, England), 25(2), 274-80 (2011)
- Authors:
- Valvassori, Samira S, Elias, Guilherme, de Souza, Bruna, Petronilho, Fabrícia, Dal-Pizzol, Felipe, Kapczinski, Flávio, Trzesniak, Clarissa, Tumas, Vitor, Dursun, Serdar, Chagas, Marcos Hortes Nisihara, Hallak, Jaime E C, Zuardi, Antonio W, Quevedo, João, Crippa, José A S
- Database ID:
- RTHC-00527
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Could CBD treat bipolar disorder?
This rat study showed CBD protected against brain damage in a model of mania, but it did not reduce manic-like behavior. CBD may have neuroprotective value rather than direct mood-stabilizing effects. Human clinical data is very limited.
What is BDNF and why does it matter?
Brain-derived neurotrophic factor (BDNF) is a protein that supports the survival and growth of brain cells. Low BDNF levels are associated with depression and bipolar disorder. CBD's ability to increase BDNF in this study suggested a neuroprotective mechanism.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00527APA
Valvassori, Samira S; Elias, Guilherme; de Souza, Bruna; Petronilho, Fabrícia; Dal-Pizzol, Felipe; Kapczinski, Flávio; Trzesniak, Clarissa; Tumas, Vitor; Dursun, Serdar; Chagas, Marcos Hortes Nisihara; Hallak, Jaime E C; Zuardi, Antonio W; Quevedo, João; Crippa, José A S. (2011). Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania.. Journal of psychopharmacology (Oxford, England), 25(2), 274-80. https://doi.org/10.1177/0269881109106925
MLA
Valvassori, Samira S, et al. "Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania.." Journal of psychopharmacology (Oxford, 2011. https://doi.org/10.1177/0269881109106925
RethinkTHC
RethinkTHC Research Database. "Effects of cannabidiol on amphetamine-induced oxidative stre..." RTHC-00527. Retrieved from https://rethinkthc.com/research/valvassori-2011-effects-of-cannabidiol-on
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.